Market revenue in 2024 | USD 11,830.9 million |
Market revenue in 2030 | USD 15,577.9 million |
Growth rate | 4.7% (CAGR from 2025 to 2030) |
Largest segment | Conventional drugs (small molecules) |
Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
Key market players worldwide | Merck & Co Inc, Roche Holding AG, Novartis AG ADR, AbbVie Inc, Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Co, Sanofi SA, GSK PLC, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical market will help companies and investors design strategic landscapes.
Conventional drugs (small molecules) was the largest segment with a revenue share of 56.81% in 2024. Horizon Databook has segmented the Saudi Arabia pharmaceutical market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia’s pharmaceutical market is primarily dominated by foreign drug makers due to the country's growing preference for branded drugs and a relatively small domestic manufacturing industry. Leading local players include Saudi Pharmaceutical Industry and Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceutical Manufacturing, Jamjoom Pharma, and Saudi Arabian Japanese Pharmaceutical (SAJA).
Despite the presence of these local players, many pharmaceuticals are imported from developed countries. Multinational companies, such as Novartis, Pfizer, Bayer, Bristol-Myers Squibb, Roche, and Eli Lilly, have a strong foothold in the Kingdom.
However, only GlaxoSmithKline and Sanofi currently manufacture locally. Many multinational companies prefer to partner with Saudi drug makers for contract manufacturing to reduce costs. Saudi Arabia also depends heavily on imports to meet its active pharmaceutical ingredient (API) requirements.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia pharmaceutical market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia pharmaceutical market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related industry reports found.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account